News and Announcements
MedAdvisor Partners with Asthma Australia
- Published November 29, 2016 4:02PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th November 2016, ASX Announcement
- MedAdvisor partners with Asthma Australia, Australia’s peak body supporting people with asthma and their carers
- Partnership aims to improve health outcomes for the estimated 2.4 million (1 in 10) Australians living with asthma, via the MedAdvisor platform
- High priority health cost reduction area: total cost of asthma in Australia is estimated to be $28 billion per annum with $1.1 billion directly related to productivity costs
- Further builds on MedAdvisor’s health association partnerships that play a key role in driving patient awareness of MedAdvisor
- In line with the Company’s strategy to enhance health outcomes for the 11m Australians living with chronic conditions and lower costs associated with poor medication adherence
MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce it has entered into a partnership with not-for-profit health association Asthma Australia. The partnership will run for an initial period of 12 months.
To view the full announcement, please click on the button below.
Company Updates
Backed By Leading Investment Groups and Family Offices
